内幕销售：Covetrus，Inc.（纳斯达克股票代码：CVET）首席执行官出售109，829.75美元的股票

Covetrus, Inc. (NASDAQ:CVET – Get Rating) CEO Benjamin Wolin sold 5,293 shares of Covetrus stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $20.75, for a total value of $109,829.75. Following the completion of the transaction, the chief executive officer now directly owns 198,238 shares in the company, valued at approximately $4,113,438.50. The sale was disclosed in a document filed with the SEC, which is available at this link.

Benjamin Wolin also recently made the following trade(s):

Get Covetrus alerts:

• On Tuesday, June 14th, Benjamin Wolin sold 5,293 shares of Covetrus stock. The stock was sold at an average price of $20.60, for a total value of $109,035.80.

Covetrus Trading Up 0.4 %

Shares of NASDAQ CVET opened at $20.80 on Friday. The stock has a market cap of $2.90 billion, a price-to-earnings ratio of -69.33 and a beta of 1.77. The business has a 50 day simple moving average of $19.78 and a 200 day simple moving average of $17.92. Covetrus, Inc. has a 52 week low of $13.39 and a 52 week high of $25.95. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.03 and a current ratio of 1.86.

Covetrus (NASDAQ:CVET – Get Rating) last posted its earnings results on Thursday, May 5th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Covetrus had a positive return on equity of 1.92% and a negative net margin of 0.87%. The company had revenue of $1.15 billion during the quarter, compared to analyst estimates of $1.15 billion. During the same quarter last year, the firm posted $0.16 earnings per share. The firm's revenue for the quarter was up 4.2% compared to the same quarter last year. On average, research analysts predict that Covetrus, Inc. will post 0.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Covetrus

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mutual of America Capital Management LLC lifted its holdings in Covetrus by 5.5% in the 1st quarter. Mutual of America Capital Management LLC now owns 14,890 shares of the company's stock worth $250,000 after purchasing an additional 772 shares during the last quarter. Eaton Vance Management lifted its holdings in shares of Covetrus by 4.8% during the fourth quarter. Eaton Vance Management now owns 19,456 shares of the company's stock worth $294,000 after buying an additional 899 shares during the last quarter. Profund Advisors LLC lifted its holdings in shares of Covetrus by 10.0% during the fourth quarter. Profund Advisors LLC now owns 12,942 shares of the company's stock worth $258,000 after buying an additional 1,175 shares during the last quarter. Parallax Volatility Advisers L.P. lifted its holdings in shares of Covetrus by 4.3% during the fourth quarter. Parallax Volatility Advisers L.P. now owns 31,673 shares of the company's stock worth $633,000 after buying an additional 1,304 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Covetrus by 6.9% during the first quarter. Teacher Retirement System of Texas now owns 21,397 shares of the company's stock worth $359,000 after buying an additional 1,385 shares during the last quarter. 93.99% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. William Blair cut Covetrus from an "outperform" rating to a "market perform" rating in a research note on Wednesday, May 25th. Raymond James cut Covetrus from an "outperform" rating to a "market perform" rating in a research note on Monday, May 23rd. The Goldman Sachs Group lowered their target price on Covetrus from $18.00 to $16.00 and set a "sell" rating on the stock in a research note on Thursday, May 19th. Morgan Stanley lifted their target price on Covetrus from $19.00 to $21.00 and gave the company an "equal weight" rating in a research note on Monday, May 23rd. Finally, Barclays cut Covetrus from an "overweight" rating to an "equal weight" rating and lowered their target price for the company from $26.00 to $21.00 in a research note on Thursday, May 26th. One investment analyst has rated the stock with a sell rating and six have given a hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $22.67.

Covetrus Company Profile

(Get Rating)

Covetrus, Inc, together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers.

Recommended Stories

• Get a free copy of the StockNews.com research report on Covetrus (CVET)
• MarketBeat: Week in Review 7/11 – 7/15
• Is Coupang's Stock On The Verge Of A Turnaround?
• Should You Have These Two Banks In Your Portfolio?
• Verint Systems Stock is a Customer Engagement Play
• Why Shopify Stock Split...And is as Shoppable as Ever

Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.